Newsletters
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Successful Placement of A$3M
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
[Video] Shareholder Webinar Recording | August 15, 2024
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
Imagion Biosystems Announces Shareholder Webinar
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to invite you to join us
Imagion Appoints New Non-Executive Director, Brett Mitchell
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today announced the appointment of Mr Brett Mitchell
[VIDEO] 2024 Annual General Meeting
Download a copy of the AGM 2024 presentation deck HERE. AGM 2024 Video Transcript: Good morning, ladies and gentlemen. My name is Robert Crew and
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
[VIDEO] EGM Recording – 13 November 2023
https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is
Quarterly Activity Report – Quarter ending 30 September 2023
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
[VIDEO] 2023 EGM Resolution Overview
Earlier this month, Imagion announced our upcoming EGM meeting to be held on 13th November, along with several resolutions to be voted on by shareholders. Here, Imagion
Preliminary Performance of Phase I Study: MagSense® HER2 Imaging Agent
Highlights • Encouraging top-line performance of world’s first molecular MRI test • Pathology results from lymph node tissue shows concordance with MRI imaging MELBOURNE —
Notice of Extraordinary General Meeting
Notice is hereby given that an Extraordinary General Meeting (EGM) of Imagion Biosystems Limited (Imagion or Company) will be held at the offices of K&L
Imagion Presents Ovarian Cancer Data at AACR Conference
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide highlights from
October 2023 Newsletter
Our October Newsletter Highlights: 🔹 Scientific poster accepted at AACR Ovarian Cancer Conference 🔹 Strategic partnership signed with Prestige Biopharma for pancreatic cancer 🔹 Imagion
Investor Update: Operating Expenses and MagSense HER2 Program
Highlights: Reduces operating expenses Update on MagSense® HER2 program MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Half-Year Results
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
Shareholder Letter from CEO July 2023
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Quarterly Activity Report and Appendix 4C for 30 June 2023
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
Imagion expands collaboration with Siemens Healthineers to United States
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Imagion set to complete the MagSense® HER2 Phase 1 Study
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
Imagion Announces New CEO
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.